Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms

• Exploring rationale for dual payload ADCs, combining synergetic efficacy of Topo1 payloads combined with diverse, alternative mechanisms to overcome patient resistance
• Spotlighting comprehensive preclinical efficacy of dual payload ADCs across in vitro and in vivo models
• Supporting promising efficacy results with preclinical pharmacology, PK/PD and safety profiles of dual cytotoxic conjugate

Speakers:

Hanspeter Gerber

Chief Scientific Officer

Sutro Biopharma